Condition: Advanced Ovarian Cancer · Platinum-resistant Ovarian Cancer · Triple Negative Breast Cancer (TNBC) · Sponsor: Epsilogen Ltd
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 IgE.
This description comes directly from the study's public registry record.
Epsilogen Clinical Trials · +44 (0) 203 657 7612 · info@epsilogen.com
Always discuss trial participation with your own doctor first.
| Bristol Haematology and Oncology Centre | Bristol, United Kingdom | Recruiting |
| Edinburgh Cancer Research Centre | Edinburgh, United Kingdom | Recruiting |
| Leeds Teaching Hospitals NHS Trust | Leeds, United Kingdom | Recruiting |
| Cambridge University - Addenbrooke's Hospital | London, United Kingdom | Recruiting |
| University College London Hospital | London, United Kingdom | Recruiting |
| Guy's Hospital | London, United Kingdom | Recruiting |
| University Hospital Southampton NHS Foundation Trust | Southampton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06547840